Houston CRO expands oncology network with addition of global clinical trial center

strategic partnership

Houston-based Proxima Clinical Research has expanded its footprint thanks to a recent partnership. Image via proximacro.com

Houston-based Proxima Clinical Research announced this month that it will expand its clinical trial offerings by adding NEXT Oncology to its Early Phase Oncology Network, or EPON.

NEXT Oncology is a Phase I clinical trial treatment center with locations in Austin, Dallas, San Antonio, and Virginia, as well as international locations in Barcelona and Madrid. These centers provide innovative and investigational treatments and therapies to patients with advanced forms of cancers.

The addition of NEXT Oncology's clinics brings Proxima's oncology network up to 14 physical locations and eight clinical practices, Robbin Frnka, executive director of clinical development and strategy at Proxima CRO tells InnovationMap.

“Early phase oncology trials are some of the most delicate and important trials to conduct, both from a science perspective and in offering hope for late-stage patients,” Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, says in a statement. “We proudly designed NEXT Oncology specifically to bring the best new agents to patients through our specially designed centers located around the world. This new relationship with Proxima CRO’s EPON will help us further enhance our mission and contribute to our life’s work of advancing cancer treatments to save more lives from cancer around the world.”

Proxima is a Houston-based contract research organization focused on supporting life science startups as they grow and scale. It was recently named to the the Inc. 5000 regional rankings for the Southwest for its fast-growing revenue.

The company launched its EPON in March to support Phase I and Phase II clinical oncology trials and a group of oncology-specific scientific experts. The Mary Crowley Cancer Research, a specialized clinical research center in Dallas, was one of the first to join the network.

"Finding the right clinical sites and investigators with the right patients is one of the biggest struggles of early phase clinical trials," Frnka says in a March statement. "Our Early Phase Oncology Network, which we're calling EPON, includes some of the most prominent investigators in early phase trials. Receiving expert feedback, insight, and guidance from this skilled scientific panel is critical to the success of these earliest phase trials."

In addition to work in the cancer field, Proxima also launched its M1 MedTech accelerator last year aimed at helping startups quickly grow their health tech businesses. Its inaugural cohort included startups with new tech and treatments for heart arrhythmias, ultrasounds, bioelectric implants in the body and more.

The company also recently expanded its footprint within the Texas Medical Center Innovation Factory.

InnovationMap spoke with Proxima CEO and Co-founder Kevin Coker on the Houston Innovators Podcast.

From Your Site Articles
This week's roundup of Houston innovators includes Kevin Coker of Proxima CRO, Gaurab Chakrabarti of Solugen, and Phil Sitter and Chris Chomenko of RepeatMD. Courtesy photos

4 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to four local innovators across industries — from marketing tech to synthetic biology — recently making headlines in Houston innovation.

Kevin Coker, CEO and co-founder of Proxima CRO, and Gaurab Chakrabarti, CEO and co-founder of Solugen

First Bight VC named two Houstonians to its board. Photos courtesy

First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups founded by Veronica Wu in January, has named two new board members: Gaurab Chakrabarti, co-founder and CEO of Solugen, and Kevin Cocker, co-founder and CEO of Proxima CRO.

"We are excited to announce the addition of Dr. Gaurab Chakrabarti and Kevin Cocker," Wu says in a press release. "These two advisors are experts in their respective fields of medicine and biotechnology. They are proven leaders of Houston-based companies, which is key to our overall growth strategy, as we seek to establish Houston as a geographic center for innovation in Synthetic Biology." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston restaurateur pivoted his restaurant marketing business amid the pandemic — to a growing industry: aesthetics. Phil Sitter took the idea and tech he created with VIPInsiders to launch RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company, on the Houston Innovators Podcast.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery." Click here to read more.

First Bight Ventures has added two Houstonians to its advisory board. Image via Getty Images

Houston-based synthetic biology investment fund taps 2 prominent advisers for board

on boarding

Earlier this year, a new synthetic biology-focused venture capital fund launched in Houston, and now its added to its esteemed set of advisers.

Veronica Wu, former Apple and Tesla exec, founded First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups, in January and named her initial board members. This month, she's added to those ranks with two Houstonians joining the advisory board — Gaurab Chakrabarti, co-founder and CEO of Solugen, and Kevin Coker, co-founder and CEO of Proxima CRO.

"We are excited to announce the addition of Dr. Gaurab Chakrabarti and Kevin Coker," Wu says in a press release. "These two advisors are experts in their respective fields of medicine and biotechnology. They are proven leaders of Houston-based companies, which is key to our overall growth strategy, as we seek to establish Houston as a geographic center for innovation in Synthetic Biology."

Gaurab co-founded Solugen, a Houston unicorn that creates enzymes that can turn sugar into chemicals, in 2016. He studied computational neuroscience at Brown University and received his master's and PhD in cancer biology and enzymology at the University of Texas.

Representing the health care side of synthetic biology, Kevin Coker runs Houston-based Proxima CRO, a regulatory and clinical partner for the emerging biotech and medical device industry. He is also the founder and partner of the M1 MedTech accelerator and the Host of the Inventing Tomorrow podcast.

"I couldn't be more excited to work with Veronica and First Bight Ventures," Coker says in the release. "The time is now for companies developing Synthetic Biology products and platforms. Much of this technology has reached commercial level maturity and we are beginning to see exciting things happen, particularly in Houston."

The two join six other advisers on the board:

  • Dr. Ethel Rubin, an experienced life sciences executive with commercialization and investment experience across multiple therapeutic areas and modalities.
  • Lekan Akinyanmi, founder and CEO of Cambridge Growth Partners, a holding company with interests in mining, finance, oil/gas, and renewable energy.
  • Dr. Guochun Liao, founder of IDbyDNA, which focuses on utilizing next-generation sequencing and AI/ML for infectious disease management.
  • Mario Maia, leader of the corporate investment arm of Novozymes.
  • Peter Oleksiak, former CFO senior vice president for DTE Energy Co., a Fortune 500 diversified energy compan.
  • Davy Wang, senior director at Oracle Cloud.
Here's what you missed at Houston House at SXSW. Photos courtesy

Podcast: Houston innovators discuss energy transition, diversity, and health tech at SXSW

Houston innovators podcast episode 125

SXSW has descended on Austin, and while the two-week conference and festival is still going strong, the Greater Houston Partnership's Houston-focused activation has wrapped for 2022.

Houston House, which first originated last year in digital form in 2021, took place Sunday, March 13, and Monday, March 14. The nine panels and two nights of networking covered topics from energy transition and med tech to diversity in venture capital and innovation in aerospace.

For SXSW badge holders, some of the Houston House discussions are available online. However if you’re not out and about at SX and you missed these incredible panels, I spoke to four Houstonians after their discussions to dig a little deeper into some key points from the panels.

Here are the Houston Innovators I spoke with at SXSW:

  • Denise Hamilton, CEO of WatchHerWork
  • Kevin Coker, president and CEO, Proxima
  • Grace Chan, investment associate at bp Ventures
  • Dale Winger, managing director of Halliburton Labs

Listen to these conversations below — or wherever you stream your podcasts — and subscribe for weekly episodes, which will return to interview-style conversations featuring Houston guests next Wednesday.

Proxima Clinical Research has its New Year's resolution and is ready to start working hands on with health tech startups. Graphic via proximacro.com

Houston organization plans to launch health tech accelerator in 2022

ready to grow

A contract research organization based in Houston has announced its new accelerator program aimed at helping startups quickly grow their health tech businesses.

Proxima Clinical Research released details of M1 MedTech, which expects to launch early next year. The CRO has raised funds to launch and invest in members of the inaugural cohort.

“Our goal is to move these companies substantially forward in a short amount of time,” says Kevin Coker, CEO of Proxima, in a news release. “Proxima is in a unique position to leverage our experienced team of regulatory, quality, and clinical experts. We won’t be working at arm’s length from these companies. We will be a big part of what they do every day.”

The program will focus on a small group of companies and the Proxima team will provide hands-on support, including instruction, workshops, and one-on-one mentoring.

“This will be a unique experience for all parties involved, as Proxima is also a young, yet established, company that is now creating a program to assist companies at an earlier stage,” says Larry Lawson, co-founder of Proxima, in the release. “Our experience in the CRO realm and ability to provide coaching in clinical, regulatory, quality, and go-to-market strategies will only strengthen M1 MedTech’s ability to support the success of emerging companies and provide more life-saving technology to the public.”

Kevin Coker and Larry Lawson co-founded Proxima in 2017. Photos courtesy

The accelerator will target Class II and III medical devices for its initial cohort. In the future, Proxima plans to expand to include an even more extensive incubator focused solely on Class III devices, according to the release.

“M1 will be a place where startups can go to receive concrete resources to further their development. The participant success is our sole focus, and the ultimate goal is to have a substantial impact on the ideation-to-market process for Class II and Class III medical devices,” says Isabella Schmitt, director of regulatory affairs at Proxima and a principal at M1, in the release. “Proxima’s specific expertise alongside our M1 partners will provide resources for all key areas of a medical device entrepreneur’s journey to market and beyond.”

The M1 MedTech applications will open online in the spring.

“We don’t view M1 as competitive to other accelerators, rather we believe it will offer a different experience. Our team will strive to create a personalized program where companies have a dedicated touch point throughout the process,” says Sean Bittner, director of programs at M1 MedTech, in the release. “We will also provide specific, tailored connections and resources vetted by our team through professional partnerships, not just a general list of industry contacts.”

This week's roundup of Houston innovators includes Emily Cisek of The Postage, Kevin Coker of Proxima Clinical Research, and Sylvia Kampshoff of Kanthaka. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — tech, health care, and more — recently making headlines in Houston innovation.


Emily Cisek, founder of The Postage

The Postage — a Houston-based company that's streamlining afterlife planning — has rolled out a new app. Photo courtesy of The Postage

Emily Cisek had a mission when she founded The Postage. She wanted to make afterlife planning simpler — and she's taken one giant step toward that goal with the company's new app.

"What we wanted to do [with the app] is make it so easy to plan your life and the end of your life using one click — as easy as it was for posting and commenting on social media," explains Cisek. "People are so used to reflecting on those behaviors and clicking one button to add a picture ... we wanted to make it that simple."

Though The Postage's website had mobile functionality, the app includes the ability to record and upload content. Whether snapping a picture of their insurance policy or recording a video to share with loved ones, The Postage app allows users to capture photos and videos directly within the app. Click here to read more.

Kevin Coker, CEO of Proxima Clinical Research

Kevin Coker, CEO of Proxima Clinical Research, say his company transform from uncertainty to almost uncontrollable growth in just 12 months. He shares what happened on this week's episode of the Houston Innovators Podcast. Photo courtesy of Proxima

After a huge dip in business due to the pandemic, a Houston company focused on supporting innovative life science companies saw 12 months of unprecedented growth. Kevin Coker, CEO of Proxima Clinical Research, says that's not only a good sign for the future of his business — but also of the future of Houston's life science sector.

"We're a good barometer for what's happening not only locally but across the country," Coker says. "As Proxima has grown, it's really show how the Houston life science market is growing."

Coker shares more about Proxima's growth and Houston's potential of being a major life science hub on the episode. Click here to read more and stream the episode.

Sylvia Kampshoff, founder of Kanthaka

Sylvia Kampshoff has launched Kanthaka's first crowdfunding campaign. Photo courtesy of Kanthaka

Sylvia Kampshoff has lofty goals for her company Kanthaka, a platform for connecting users to personal trainers across over a dozen cities. With the launch of a new $1 million crowdfunding raise, Kampshoff is one step closer to growing her business according to these goals.

"Our vision is to become Amazon for health & fitness and the go-to provider to live a longer, happier and healthier life," Kampshoff says. "We couldn't be more excited about this journey." Click here to read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Musk’s SpaceX spends $17B to acquire spectrum licenses from EchoStar

SpaceX Update

Elon Musk’s SpaceX has reached a deal worth about $17 billion with EchoStar for spectrum licenses that it will use to beef up its Starlink satellite network.

The deal for EchoStar’s AWS-4 and H-block spectrum licenses includes up to $8.5 billion in cash and up to $8.5 billion in SpaceX stock. SpaceX will make approximately $2 billion in cash interest payments on EchoStar debt through November 2027.

SpaceX and EchoStar will enter into a long-term commercial agreement which will allow EchoStar’s Boost Mobile subscribers to access SpaceX’s next generation Starlink Direct to Cell service.

Shares of EchoStar surged 19% before the market opened Monday.

Last month AT&T said that it will spend $23 billion to acquire wireless spectrum licenses from EchoStar, a significant expansion of its low- and mid-band coverage networks.

EchoStar said that it anticipates that the AT&T deal and the SpaceX transaction will resolve recent inquiries from the Federal Communications Commission about the rollout of 5G technology in the U.S. The FCC had been calling for hearings on whether Echostar was properly using the spectrum that it is now selling, and its efforts to make 5G more available to communities.

EchoStar said Monday that it will use the proceeds from the sale partly to pay down debt. Current operations of Dish TV, Sling and Hughes will not be impacted, the company said.

Houston students develop cost-effective glove to treat Parkinson's symptoms

smart glove

Two Rice undergraduate engineering students have developed a non-invasive vibrotactile glove that aims to alleviate the symptoms of Parkinson’s disease through therapeutic vibrations.

Emmie Casey and Tomi Kuye developed the project with support from the Oshman Engineering Design Kitchen (OEDK) and guidance from its director, Maria Oden, and Rice lecturer Heather Bisesti, according to a news release from the university.

The team based the design on research from the Peter Tass Lab at Stanford University, which explored how randomized vibratory stimuli delivered to the fingertips could help rewire misfiring neurons in the brain—a key component of Parkinson’s disease.

Clinical trials from Stanford showed that coordinated reset stimulation from the vibrations helped patients regain motor control and reduced abnormal brain activity. The effects lasted even after users removed the vibrotactile gloves.

Casey and Kuye set out to replicate the breakthrough at a lower cost. Their prototype replaced the expensive motors used in previous designs with motors found in smartphones that create similar tiny vibrations. They then embedded the motors into each fingertip of a wireless glove.

“We wanted to take this breakthrough and make it accessible to people who would never be able to afford an expensive medical device,” Casey said in the release. “We set out to design a glove that delivers the same therapeutic vibrations but at a fraction of the cost.”

Rice’s design also targets the root of the neurological disruption and attempts to retrain the brain. An early prototype was given to a family friend who had an early onset of the disease. According to anecdotal data from Rice, after six months of regularly using the gloves, the user was able to walk unaided.

“We’re not claiming it’s a cure,” Kuye said in the release. “But if it can give people just a little more control, a little more freedom, that’s life-changing.”

Casey and Kuye are working to develop a commercial version of the glove priced at $250. They are taking preorders and hope to release 500 pairs of gloves this fall. They've also published an open-source instruction manual online for others who want to try to build their own glove at home. They have also formed a nonprofit and plan to use a sliding scale price model to help users manage the cost.

“This project exemplifies what we strive for at the OEDK — empowering students to translate cutting-edge research into real-world solutions,” Oden added in the release. “Emmie and Tomi have shown extraordinary initiative and empathy in developing a device that could bring meaningful relief to people living with Parkinson’s, no matter their resources.”

New Austin tower eclipses Houston landmark as Texas' tallest building

Tallest in Texas

Texas officially has a new tallest tower. The title moves from Houston, for the JPMorgan Chase Tower, to Austin, for Waterline at 98 Red River St. The new tower will contain mixed-use spaces including apartments, offices, a hotel, restaurants, and retail. It is scheduled to open in full in 2026.

Waterline held a "topping out" ceremony in August, when the final beam was added to the top of the tower. It now reaches 74 stories and 1,025 feet — just 23 feet taller than the JPMorgan Chase Tower.

Waterline height comparison Waterline is now the tallest building in Texas.Graphic courtesy of Lincoln Property Company

According to a press release, hundreds of construction workers and team project members attended the Waterline ceremony, and more than 4,750 people have worked on it since the project broke ground in 2022. An estimated 875 people were working onsite every day at the busiest time for construction.

The Waterline site is on a 3.3-acre campus with lots of views of Waller Creek and Lady Bird Lake. The building contains space for 352 luxury apartments, 700,000 square feet of offices, a hotel called 1 Hotel Austin with 251 rooms, and 24,000 square feet of retail stores and restaurants.

The only space that is open to new tenants already is the office space, with residential soon to follow. The hotel and residential units are expected to open in fall 2026.

Waterline tower Austin A view from above, shot by drone.Photo courtesy of Lincoln Property Company and Kairoi Residential

“Seamlessly integrated with Waller Creek, Waterloo Greenway and the hike-and-bike trail around Lady Bird Lake, Waterline will quickly become a top downtown destination and activity center," said Lincoln executive vice president Seth Johnston in a press release. Project improvements will also make it far easier for people to access all of the public amenities in this area from Rainey Street, the new Austin Convention Center, and the rest of the Central Business District."

---

This article originally appeared on CultureMap.com.

View All Listings